Full-Time

Lab Manager

Immunoassay Development

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$128k - $150k/yr

+ Equity component

San Carlos, CA, USA

In Person

Onsite at least 4 days per week.

Bachelor's, Master's

Category
Lab & Research (1)
Required Skills
Inventory Management
Data Analysis

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • A Master of Science degree in Biochemistry, Immunology, Analytical Chemistry, Biological Sciences, or a related discipline with at least 3 years of relevant biopharmaceutical industry laboratory experience, or a Bachelor of Science degree in a related discipline with at least 5 years of relevant biopharmaceutical industry laboratory experience; other combinations of education and experience may be considered.
  • Hands-on experience supporting monoclonal antibody generation, screening, characterization, qualification, conjugation, labeling, or lifecycle management.
  • Experience supporting critical reagent, reference standard, assay control, calibrator, or customized assay material management for immunoassays or ligand-binding assays.
  • Experience supporting general laboratory operations, including reagent and consumable planning, sample logistics, inventory management, equipment coordination, laboratory organization, documentation, and daily operational support.
  • Experience supporting laboratory procurement or supply coordination, including purchase request support, order tracking, vendor communication, stock monitoring, and consumable replenishment.
  • Experience supporting reagent or reference material stability studies, including timepoint tracking, sample pull coordination, testing support, data tracking, trend monitoring, and documentation.
  • Experience with immunoassay platforms such as enzyme-linked immunosorbent assay, Meso Scale Discovery, electrochemiluminescence-based assays, bead-based assays, multiplex assays, or other ligand-binding assay technologies.
  • Experience managing inventories, sample tracking, reagent records, procurement records, documentation systems, and laboratory schedules.
  • Ability to coordinate multiple laboratory priorities, material needs, testing schedules, procurement timelines, vendor interactions, and documentation deliverables.
  • Strong written and verbal communication skills to communicate material status, inventory risks, study logistics, procurement needs, technical observations, and operational priorities.
  • Commitment to laboratory safety, data integrity, documentation quality, scientific excellence, accountability, supply continuity, and continuous improvement.
Responsibilities
  • Support daily operations for the CMC Immunoassay, including laboratory scheduling, reagent and consumable readiness, sample coordination, equipment availability, laboratory organization, study logistics, inventory tracking, documentation, and issue escalation.
  • Support general laboratory management activities, including lab organization, space utilization, equipment tracking, instrument maintenance coordination, consumable stocking, safety readiness, sample flow, reagent flow, and day-to-day operational troubleshooting.
  • Coordinate laboratory logistics, including sample receipt, sample storage, reagent receipt, material aliquoting, labeling, chain of custody, shipment coordination, cold-chain handling, material transfers, and communication with internal and external stakeholders.
  • Support procurement activities by identifying laboratory supply needs, coordinating purchase requests, tracking orders, following up with vendors, supporting new vendor setup, maintaining stock levels, and ensuring timely availability of reagents, consumables, equipment, and customized assay materials.
  • Maintain inventory systems for critical reagents, reference standards, customized assay materials, consumables, laboratory supplies, and assay components, including usage tracking, expiry or retest tracking, reserve stock monitoring, replenishment planning, and documentation.
  • Support laboratory setup, organization, and operational readiness, including equipment onboarding, reagent and consumable stocking, workflow setup, storage organization, inventory system implementation, and laboratory process improvement.
  • Support antibody reagent generation, characterization, qualification, stability monitoring, and inventory management for capture antibodies, detection antibodies, monoclonal antibodies, polyclonal antibodies, labeled antibodies, and other assay-specific binding reagents.
  • Support monoclonal antibody generation and characterization, including antigen preparation, screening support, clone tracking, purification support, conjugation or labeling support, specificity assessment, binding evaluation, and assay suitability testing.
  • Support reference standard and assay control activities, including material preparation, aliquoting, labeling, storage, qualification-support testing, bridging-support testing, inventory control, stability tracking, and replenishment planning.
  • Support customized immunoassay material management, including Meso Scale Discovery plates, coated plates, labeled detection reagents, multiplex assay components, customized assay kits, buffers, blocking reagents, and other platform-specific critical materials.
  • Coordinate critical reagent and reference material stability activities, including timepoint scheduling, sample pull coordination, testing readiness, data tracking, trend documentation, inventory impact assessment, and report support.
  • Maintain inspection-ready documentation for critical reagents, reference materials, customized assay materials, certificates of analysis, lot history records, usage logs, stability records, procurement records, inventory records, and qualification documentation.
  • Perform hands-on laboratory testing for reagent characterization, reference material characterization, lot comparison, stability studies, qualification support, bridging support, method development, platform evaluation, and routine analytical testing.
  • Support contract research organization, contract development and manufacturing organization, contract testing laboratory, reagent vendor, and technology partner activities, including material shipment coordination, purchase order tracking, study tracking, communication support, data receipt, documentation review, deliverable tracking, and timeline follow-up.
  • Support immunoassay development, optimization, troubleshooting, platform evaluation, method transfer, validation readiness, and routine testing as needed.
  • Work with scientists, senior scientists, Associate Directors, and the Director on laboratory planning, reagent planning, procurement planning, study scheduling, inventory review, and cross-functional project needs.
  • Contribute to laboratory process improvements involving inventory workflows, reagent request processes, sample tracking processes, procurement workflows, equipment readiness tracking, documentation templates, and laboratory organization standards.
  • Support good laboratory practices, safety expectations, data integrity, documentation quality, and operational discipline across the CMC Immunoassay.
Desired Qualifications
  • Experience supporting outsourced reagent generation, characterization, qualification, stability, custom assay material production, or testing activities with contract research organizations, contract development and manufacturing organizations, contract testing laboratories, reagent vendors, or technology partners.
  • Experience working in or supporting good manufacturing practice-regulated analytical environments.
  • Experience establishing, organizing, or scaling a laboratory, including equipment onboarding, consumable stocking, reagent storage setup, inventory system implementation, workflow organization, and operational readiness.
  • Experience with antibody engineering, recombinant antibody production, hybridoma workflows, antibody purification, antibody conjugation, biotinylation, ruthenium labeling, fluorescent labeling, or bead conjugation.
  • Experience with Meso Scale Discovery custom plates, labeled detection reagents, multiplex panel materials, or customized assay kits.
  • Experience supporting critical reagent control strategies, reagent history files, lifecycle management plans, stability protocols, bridging protocols, inventory control systems, and reagent replenishment strategies.
  • Experience with laboratory procurement systems, vendor onboarding, purchase order tracking, electronic inventory systems, laboratory information management systems, electronic laboratory notebooks, and digital data analysis tools.
  • Experience supporting vaccine, biologics, conjugated vaccine, multivalent vaccine, or complex analytical development programs.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 enrollment completion removed major execution risk across three Phase 3 trials.
  • VAX-A1 entered first-in-human dosing in June 2026, expanding the pipeline beyond pneumococcus.
  • PCV31 adult data could support a BLA submission and U.S. commercial launch in 2027.

What critics are saying

  • OPUS-1 topline data lands in Q4 2026; any miss crushes VAX-31's valuation.
  • June 30, 2026 cash was $2.51 billion, but operating burn stays punishing.
  • VAX-31 failure leaves Vaxcyte a pre-revenue vaccine company with no approved products.

What makes Vaxcyte unique

  • Vaxcyte's XpressCF platform and 31-valent PCV31 target higher serotype coverage than PCV20.
  • OPUS-1, OPUS-2, and OPUS-3 fully enrolled 6,191 adults by August 2026.
  • Thermo Fisher's up to $1 billion U.S. fill-finish deal secures commercial manufacturing capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

1%
Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.

GlobeNewswire
Apr 7th, 2026
Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference.

Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference. April 07, 2026 16:05 ET | Source: Vaxcyte, Inc. SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company's carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company's PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF(R), its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com. Jeff Macdonald, Executive Director, Investor Relations Vaxcyte, Inc. 917-371-0940 [email protected]

MJH Life Sciences
Mar 28th, 2026
Vaxcyte announces significant development of first-of-its-kind PCV31.

Vaxcyte announces significant development of first-of-its-kind PCV31. With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden. Vaxcyte recently announced significant progress in the clinical development of VAX-31, its 31-valent pneumococcal conjugate vaccine (PCV31) candidate, according to a news release.[1] As the highest-valent PCV currently under development, VAX-31 is being positioned as a potential best-in-class protection against pneumococcal disease for both adults and infants. "The continued advancement of VAX-31 in adults reflects disciplined execution across our phase 3 clinical program, which was finalized in consultation and alignment with the FDA, as we work toward delivering a best-in-class, next-generation PCV with the potential to set a new standard of care for adults and children," Grant Pickering, CEO and co-founder of Vaxcyte, said in the news release. "In adults, evaluating VAX-31 in settings that reflect real-world vaccination practice, including coadministration with a seasonal influenza vaccine and in individuals with prior pneumococcal vaccination, will provide important insights into how VAX-31 is expected to perform across the adult population." Dosing has commenced in the phase 3 OPUS-2 trial, which evaluates the vaccine's performance when administered concomitantly with seasonal influenza vaccines in pneumococcal-naïve adults 50 years and older. Simultaneously, Vaxcyte completed enrollment for a phase 2 infant dose-finding study, marking a critical step toward addressing the leading cause of vaccine-preventable deaths in children under 5 globally.[1] For pharmacists, who serve as the most accessible members of the health care team, these advancements represent a vital expansion of the tools available to combat infectious disease burden, which saw invasive pneumococcal disease (IPD) incidence nearly double between 2012 and 2024.[2,3] The clinical relevance of VAX-31 is underscored by its design to cover approximately 95% of invasive pneumococcal disease (IPD)-causing serotypes circulating in US adults over 50 years.[1] This broad spectrum is necessary because, despite the efficacy of current options like PCV20 and the recently approved PCV21, the phenomenon of serotype replacement continues to push nonvaccine serotypes into prominence.[3] To provide pharmacists and the FDA with real-world data, the OPUS-2 trial utilizes a randomized, double-blind approach to compare concomitant and sequential administration with flu shots, and the upcoming OPUS-3 study will specifically evaluate VAX-31 in adults who have previously received other pneumococcal vaccines, such as the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or PCV20.[1] The push for higher valency, however, brings technical challenges regarding immunogenicity. Research comparing earlier vaccines like PCV7 and PCV13 with newer PCV15 and PCV20 formulations suggested that increasing the number of polysaccharides can sometimes result in lower antibody responses for common serotypes, according to the Canada Communicable Disease Report.[4] To mitigate this, some pipeline candidates - such as Inventprise's PCV25 - are utilizing innovative hydrazide-polyethylene glycol-hydrazide (Hz-PEG-Hz) linker technology to reduce carrier-induced immune interference.[2] Vaxcyte's own platform similarly aims to maintain robust immune responses while expanding coverage, a necessity as the CDC recently lowered the routine vaccination age to 50 years old.[1,5,6] In the pediatric sector, VAX-31 is designed to protect against approximately 92% of IPD serotypes and 96% of acute otitis media cases in children.[1] This is particularly important because PCVs provide nasal immunity by stimulating antibodies in the nasal mucosa, which prevents colonization and is a feature missing from PPSV23.[6] Furthermore, dosing schedules remain a point of clinical discussion, and the World Health Organization supports a 2+1 schedule for healthy children. However, some data indicates that a 3+1 schedule provides superiority.[4] Vaxcyte's ongoing infant study follows the 4-dose series to ensure maximum protection.[1] As the landscape shifts toward sophisticated platforms like Vaxcyte's cell-free protein synthesis system, the goal remains a serotype-independent vaccine - the holy grail of the pneumococcal vaccine industry.[1,7] Pharmacists can bridge current gaps by using the PneumoRecs VaxAdvisor app to navigate complex guidelines and stay updated on Vaxcyte's expanding pipeline, which also includes candidates for Group A Streptococcus and Shigella.[1,2,5] With Vaxcyte committing up to $1 billion toward US manufacturing, the infrastructure is being set to support these next-generation preventions.[1] "We expect to announce topline data from the ongoing OPUS-1 Phase 3 pivotal, noninferiority trial in the fourth quarter of 2026 and results from these additional Phase 3 adult studies in the first half of 2027, keeping us on track toward a planned Biologics License Application submission," concluded Pickering, according to the release. Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for its. References. 1. Vaxcyte advances adult and infant programs for VAX-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine. News release. Vaxcyte, inc. january 22, 2026. Accessed march 18, 2026. https://www.biospace.com/press-releases/vaxcyte-advances-adult-and-infant-programs-for-vax-31-a-potential-best-in-class-next-generation-pneumococcal-conjugate-vaccine. 2. Nowosielski B. New 25-valent pneumococcal vaccine shows promise in global disease coverage. Drug Topics. March 13, 2026. Accessed march 18, 2026. https://www.drugtopics.com/view/new-25-valent-pneumococcal-vaccine-shows-promise-in-global-disease-coverage. 3. Nowosielski B. Rise in IPD calls for development of more pneumococcal vaccines. Drug Topics. November 17, 2025. Accessed march 18, 2026. https://www.drugtopics.com/view/rise-in-ipd-calls-for-development-of-more-pneumococcal-vaccines. 4. De wals P. PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity? Can commun dis rep. 2024 jan 1;50(1-2):35-39. doi: 10.14745/ccdr.v50i12a04. 5. Pneumococcal vaccine recommendations. CDC. February 25, 2026. Accessed march 18, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html. 6. Katella K. Should i get the pneumococcal vaccine? 5 things to know. Yale medicine. December 12, 2024. Accessed march 18, 2026. https://www.yalemedicine.org/news/should-i-get-the-pneumococcal-vaccine-5-things-to-know. 7. Musher DM, anderson R, feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia (nathan). 2022 sep 25;14(1):5. doi: 10.1186/s41479-022-00097-y. Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Simply Wall St
Mar 8th, 2026
Vaxcyte reports $766M loss and raises $408M in follow-on offering amid widening cash burn

Vaxcyte reported a full-year 2025 net loss of $766.63 million and completed a $408.1 million follow-on equity offering in February 2026. The biotech company also filed an additional $500 million at-the-market programme and a $473.86 million shelf registration for employee stock plans. The funding moves underscore Vaxcyte's reliance on equity financing to support its pneumococcal vaccine pipeline, particularly its OPUS Phase 3 programme for VAX-31. Whilst the capital raises improve funding flexibility, they raise concerns about shareholder dilution and mounting cash burn. Simply Wall St community fair value estimates for Vaxcyte range widely from $10.90 to $109 per share. The company's shares may be trading 35% above fair value despite recent declines, according to the analysis.

Vaxcyte
Feb 3rd, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share.